- Research article
- Open Access
Evaluation of Dimebon in cellular model of Huntington's disease
© Wu et al; licensee BioMed Central Ltd. 2008
- Received: 21 August 2008
- Accepted: 21 October 2008
- Published: 21 October 2008
Dimebon is an antihistamine compound with a long history of clinical use in Russia. Recently, Dimebon has been proposed to be useful for treating neurodegenerative disorders. It has demonstrated efficacy in phase II Alzheimer's disease (AD) and Huntington's disease (HD) clinical trials. The mechanisms responsible for the beneficial actions of Dimebon in AD and HD remain unclear. It has been suggested that Dimebon may act by blocking NMDA receptors or voltage-gated Ca2+ channels and by preventing mitochondrial permeability pore transition.
We evaluated the effects of Dimebon in experiments with primary striatal neuronal cultures (MSN) from wild type (WT) mice and YAC128 HD transgenic mice. We found that Dimebon acts as an inhibitor of NMDA receptors (IC50 = 10 μM) and voltage-gated calcium channels (IC50 = 50 μM) in WT and YAC128 MSN. We further found that application of 50 μM Dimebon stabilized glutamate-induced Ca2+ signals in YAC128 MSN and protected cultured YAC128 MSN from glutamate-induced apoptosis. Lower concentrations of Dimebon (5 μM and 10 μM) did not stabilize glutamate-induced Ca2+ signals and did not exert neuroprotective effects in experiments with YAC128 MSN. Evaluation of Dimebon against a set of biochemical targets indicated that Dimebon inhibits α-Adrenergic receptors (α1A, α1B, α1D, and α2A), Histamine H1 and H2 receptors and Serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors with high affinity. Dimebon also had significant effect on a number of additional receptors.
Our results suggest that Ca2+ and mitochondria stabilizing effects may, in part, be responsible for beneficial clinical effects of Dimebon. However, the high concentrations of Dimebon required to achieve Ca2+ stabilizing and neuroprotective effects in our in vitro studies (50 μM) indicate that properties of Dimebon as cognitive enhancer are most likely due to potent inhibition of H1 histamine receptors. It is also possible that Dimebon acts on novel high affinity targets not present in cultured MSN preparation. Unbiased evaluation of Dimebon against a set of biochemical targets indicated that Dimebon efficiently inhibited a number of additional receptors. Potential interactions with these receptors need to be considered in interpretation of results obtained with Dimebon in clinical trials.
- Mitochondrial Permeability Pore Transition
- Medium Spiny Neuron
- YAC128 Mouse
- Biochemical Target
Huntington disease (HD) is an inherited, incurable, autosomal dominant disease caused by the expansion of CAG trinucleotide repeats in the first exon of the huntingtin gene [1, 2]. It is characterized by progressive neurodegeneration resulting in motor abnormalities including chorea and psychiatric disturbance with gradual dementia. HD is fatal and causes death within 15–20 years of the onset of the symptoms. The mutant huntingtin (Htt) with expanded polyglutamine (polyQ) is widely expressed in the brain and peripheral tissues but causes selective and most prominent loss of medium spiny neurons in striatum (MSN) which leads to the major clinical abnormalities that characterize the disease. The exact cause of neuronal loss in HD remains unknown . Recent evidence indicates that dysregulation of glutamate and Ca2+ (calcium) signaling in MSN play an important role in HD pathogenesis . The "Ca2+ hypothesis of HD" suggests that Ca2+ signaling inhibitors may have a therapeutic value for treatment of HD . Abnormal neuronal Ca2+ signaling has also been proposed to play an important role in Alzheimer's disease [5, 6].
Dimebon is a drug that has been developed and used as an antihistamine in Russia since 1983. Recently, Dimebon has been proposed to be useful for treating neurodegenerative disorders . Dimebon demonstrated significant positive effects in six-month randomized, double-blinded, placebo-controlled phase II trial of 183 patients with mild to moderate Alzheimer's disease (AD) conducted by Medivation . The phase III trial of Dimebon in AD will soon be initiated. Dimebon also demonstrated efficacy in phase 2 trial of patients with Huntington's disease (HD) conducted by Medivation and Huntington Study Group (DIMOND). Despite extremely encouraging results in clinical trials, the mechanisms responsible for beneficial actions of Dimebon in AD and HD remain poorly understood. Previous reports suggested that Dimebon may act as an inhibitor of NMDA receptors , voltage-gated Ca2+ channels  or as a blocker of mitochondrial permeability transition pore . These potential targets indicated that Dimebon may act by stabilizing neuronal Ca2+ signaling, which may explain clinical benefits observed in HD and AD trials. In the present study, we evaluated the ability of Dimebon to inhibit NMDA receptors and voltage-gated Ca2+ channels in cultured MSN from wild type mice and from the YAC128 HD transgenic mice model. We also evaluated neuroprotective effects of Dimebon in previously developed glutamate-toxicity assay with cultured YAC128 MSN . We concluded that Ca2+ and the mitochondria stabilizing effects of Dimebon may only in part be responsible for beneficial effects in human clinical trials and additional mechanisms of Dimebon's actions need to be uncovered to explain its beneficial clinical actions in HD and AD trials.
Primary neuronal cultures
YAC128 mice (FVBN/NJ background strain) were obtained from Jackson Labs (stock number 004938). The male YAC128 mice were crossed to wild type (WT) female FVBN/NJ mice and P1-P2 pups were collected and genotyped by PCR. The primary cultures of striatal medium spiny neurons (MSN) were established from YAC128 and control wild type pups as we previously described [12–15]. Striata were dissected, diced and digested with trypsin. After dissociation, neurons were plated on poly-L-lysine (Sigma) coated 12 mm round coverslips (Assistent) in Neurobasal-A medium supplemented with 2% B27, 1 mM glutamine and penicillin-streptomycin (all from Invitrogen) and kept at 37°C in a 5% CO2 environment.
Calcium imaging experiments
Ca2+ imaging experiments with 13–14 DIV (days in vitro) MSN cultures were performed as previously described [12, 14–16], using a DeltaRAM illuminator, an IC-300 camera, and IMAGEMASTER PRO software (all from PTI). The MSN were loaded with 5 μM fura-2 AM (Molecular Probes) for 45 min at 37°C in artificial cerebrospinal fluid (ACSF, containing the following: 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM Hepes, pH7.3). Coverslips were mounted onto a recording/perfusion chamber (RC-26G, Warner Instruments) and positioned on the movable stage of an Olympus (Melville) IX-70 inverted microscope. The cells were maintained in ACSF at 37°C during experiments (PH1 heater, Warner Instruments). Images at 340 and 380 nm excitation wavelengths were acquired every 6 s and shown as 340/380 image ratios. Baseline (1–3 min) measurements were obtained before first pulse of glutamate. The 20 μM glutamate solution was dissolved in ACSF and 1-min pulses of 37°C glutamate solution (SH-27B in-line solution heater, Warner Instruments) were applied by using a valve controller (VC-6, Warner Instruments) driven by a square-pulse electrical wave-form generator (Model 148A, Wavetek). 10 μM or 50 μM Dimebon was dissolved in ACSF or 20 μM glutamate solution for the Dimebon application.
Electrophysiology for NMDAR and voltage-gated Ca2+channels
Whole-cell patch-clamp recordings of NMDAR activity were performed with cultured MSN from WT and YAC128 mice at DIV9-10 as we previously described . Medium spiny neurons were distinguished based on morphological identification and membrane capacitance ranging from 4–10 pF. A multi-barrel perfusion system was employed to achieve a rapid exchange of extracellular solutions as we previously described . All drugs were prepared according to the specifications of the manufacturers and applied with a gravity-fed "sewer pipe" capillary array. Whole-cell currents were recorded using Axopatch 200B amplifiers (Axon Instruments). Data were filtered at 2 kHz and digitized at 5 Hz using a Digidata 1200 DAC unit (Axon Instruments). The online acquisition was done using pCLAMP software (Version 8, Axon Instruments). Cultured MSN were held at VH = -60 mV membrane potential. Standard extracellular solutions contained 140 mM NaCl, 5 mM KCl, 2.0 mM CaCl2, 10 mM HEPES (pH 7.4; 310 mOsm). The pipette solution contained 135 mM CsMeSO4, 10 mM HEPES, 5 mM 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, 3 mM MgATP, 1 mM MgCl2, 0.3 mM GTP-tris. In all experiments, 50 μM glycine was added to both control and NMDA-containing extracellular solutions. 10 μM CNQX and 0.1 μM TTX were added to the extracellular recording solution immediately before each experiment to block AMPA/kainate-type glutamate receptors and voltage-gated sodium currents, respectively.
Whole-cell patch-clamp recordings of voltage gated Ca2+ currents in cultured MSN at DIV9 were performed according to the published procedures . The recording chamber was perfused with extracellular solution containing 140 mM TEA-Cl, 10 mM BaCl2, 10 mM HEPES, 20 mM glucose, 0.001 mM tetrodotoxin (TTX), pH 7.4, with TEA-OH, 310 mOsm. The pipette solution contained 110 mM CsCl, 10 mM EGTA, 4 mM ATP-Mg, 0.3 mM GTP-Na, 25 mM HEPES, 10 mM Tris-phosphocreatine, 20 units/ml creatine phosphokinase, pH 7.3, with CsOH, 290 mOsm. Ba2+ current traces were corrected for linear capacitive leak with online P/6 trace subtraction. MSN were voltage clamped at -80 mV, and test pulses were applied at 10 s intervals.
In vitroHD assay
The in vitro HD assay with wild type and YAC128 MSN cultures was conduced as previously described [12, 13]. Dimebon was added to the 14 DIV MSN at the final concentration of 5 μM, 10 μM or 50 μM. After 30 minutes incubation with Dimebon, the MSN were exposed for 7 h to 250 μM glutamate in Neurobasal-A added to the culture medium. During exposure to glutamate, the cells were maintained in a cell culture incubator (humidified 5% CO2, 37°C). Immediately after the treatment with glutamate, neurons were fixed for 30 min in 4% paraformaldehyde plus 4% sucrose in PBS (pH7.4), permeabilized for 5 min in 0.25% Triton-X-100, and stained by using the DeadEnd fluorometric TUNEL System (Promega). Nuclei were counterstained with 5 μM propidium iodine (PI) (Molecular Probes). Coverslips were extensively washed with PBS and mounted in Mowiol 4–88 (Polysciences). For quantification, six to eight randomly chosen microscopic fields containing 100–300 MSN each were cell-counted for YAC128 and wild type cultures. The number of TUNEL-positive neuronal nuclei was calculated as a fraction of PI-positive neuronal nuclei in each microscopic field. The fractions of TUNEL-positive nuclei determined for each microscopic field were averaged and the results are presented as means ± SE (n = number of fields counted).
Evaluation against biochemical targets
The activity of Dimebon against selected set of biochemical targets was performed by MDS Pharma Services http://discovery.mdsps.com/. The Dimebon was provided to MDS Pharma as dry powder, dissolved in DMSO and tested in 10 μM concentrations. The standard Lead Profiling + CYP450 screen was performed according to MDS Pharma specifications with additional custom-chosen targets added to the screen as indicated.
All experiments were repeated at least three times. Data were evaluated for statistical significance by analysis using SigmaPlot t-test or One-Way ANOVA. Statistical difference was considered to be significant if p < 0.05.
Dimebon inhibits glutamate-induced Ca2+increase in YAC128 MSN
NMDAR inhibition by Dimebon
Voltage-gated calcium channel inhibition by Dimebon
Neuroprotective effects of Dimebon in in vitroHD assay
Effects of Dimebon on glutamate-induced apoptosis in WT and YAC128 MSN.
WT (% TUNEL-positive)
YAC128 (% TUNEL-positive)
0 μM glutamate
250 μM glutamate
0 μM glutamate
250 μM glutamate
7.53 ± 2.15
(7.25 ± 1.11)a
24.14 ± 3.22
(26.26 ± 3.50)
7.78 ± 1.29
(10.93 ± 2.89)
47.35 ± 1.95
(54.53 ± 5.40)
8.34 ± 1.40
(5.88 ± 0.62)
39.58 ± 5.01
(37.59 ± 3.71)
7.86 ± 1.21
(7.24 ± 0.92)
54.90 ± 7.17
(65.84 ± 6.27)
7.14 ± 1.19
(5.88 ± 0.62)
34.50 ± 2.12
(37.59 ± 3.71)
6.19 ± 0.96
(7.24 ± 0.92)
41.08 ± 3.25*
(65.84 ± 6.27)
Evaluation of Dimebon against a set of biochemical targets
Dimebon demonstrated significant positive effects in phase II AD clinical trial conducted by Medivation in Russia . It has also demonstrated efficacy in a phase 2 trial of patients with Huntington's disease (HD) conducted by Medivation and Huntington Study Group (DIMOND). Despite extremely encouraging results in clinical trials, the mechanisms responsible for the beneficial actions of Dimebon in AD and HD remain poorly understood. Here, we evaluated neuroprotective effects of Dimebon in a previously developed cellular model of HD . We also tested the ability of Dimebon to function as a "Ca2+ signaling stabilizer" and an inhibitor of NMDAR and voltage-gated Ca2+ channels in Ca2+ imaging and electrophysiological experiments with wild type and YAC128 MSN cultures. Consistent with the previous reports [9, 10], we found that Dimebon indeed inhibits NMDAR and voltage-gated Ca2+ channels. The IC50 for inhibitory actions of Dimebon was equal to 10 μM for NMDAR and 50 μM for voltage-gated Ca2+ channels in our experiments (Figs 3B and 4B). At 50 μM concentration, Dimebon also exerted Ca2+ stabilizing and neuroprotective effects in YAC128 MSN preparation (Figs 2G and 5C, Table 1). At the concentration of 10 μM, Dimebon was not effective in these in vitro assays (Figs 2G and 5B, Table 1). Similar efficacy of Dimebon was observed in experiments with the Drosophila model of HD . Consistent with our findings, neuroprotective effects of Dimebon in the Drosophila model of HD were observed in the 50 – 100 μM concentration range . The protective effects of Dimebon in the in vitro HD assay are in quantitative agreement with the "Ca2+ stabilizing" effects of Dimebon (Fig 2G). Thus, neuroprotective effects of Dimebon observed in our experiments (Table 1, Fig 5C) most likely can be explained by "Ca2+ stabilizing" effects of Dimebon resulting from inhibition of NMDAR (Fig 3) and voltage-gated Ca2+ channels (Fig 4). It is also possible that Dimebon exerts additional beneficial actions at the level of neuronal mitochondria . The concentration of Dimebon required to inhibit mitochondrial permeability pore transition in isolated mitochondria was in the range of 50 μM , the same concentration range as the neuroprotective effects observed in our experiments with YAC128 MSN cultures (Fig 5C, Table 1).
Using an identical experimental approach, in previous studies we demonstrated that clinically relevant NMDAR antagonist memantine (Namenda) was protective in the YAC128 MSN glutamate toxicity assay at 10 μM concentration . Thus, Dimebon is 5-fold less effective than memantine when tested in the in vitro HD model. We also previously demonstrated that clinically relevant putative mitochondrial permeability pore inhibitors Nortriptyline, Desipramine, Trifluoperazine, and Maprotiline  were also protective in YAC128 MSN toxicity assay at 2 μM concentration . The Dimebon was 25-fold less effective than these compounds when tested in the in vitro HD model.
Unbiased evaluation of Dimebon against a set of biochemical targets indicated that Dimebon efficiently inhibits α-Adrenergic receptors (α1A, α1B, α1D, and α2A), Histamine H1 and H2 receptors and Serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors with high affinity (Fig 6). Dimebon also had significant effect on Dopamine D1, D2S, D3 receptors, Imidazoline I2 receptor, Serotonin 5-HT2 and 5-HT2B receptors (Fig 6). Interactions with these receptors need to be taken into consideration in interpretation of results obtained with Dimebon in HD and AD clinical trials.
From our results, we concluded that the "Ca2+ stabilizing" effects of Dimebon may, in part, be responsible for the clinical benefits observed in HD and AD trials. However, 50 μM concentration of Dimebon that is required to achieve "Ca2+ stabilizing" and neuroprotective effects in our experiments is not likely to be achieved in human trials. In AD trials of Dimebon, the patients received 20 mg pills , which should not lead to concentrations higher than 0.6 μM assuming an ideal absorption and blood-brain-barrier brain permeability profile. Thus, most beneficial effects of Dimebon are likely to be due to its properties as a cognitive enhancer based on its ability to inhibit H1 histamine receptors with IC50 = 3.4 nM . It is also possible that Dimebon acts on novel high affinity targets not present in cultured MSN preparation. Unbiased evaluation of Dimebon against a set of biochemical targets indicated that Dimebon efficiently inhibits α-Adrenergic receptors (α1A, α1B, α1D, and α2A), Histamine H1 and H2 receptors and Serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors with high affinity. Dimebon also had significant effect on Dopamine D1, D2S, D3 receptors, Imidazoline I2 receptor, Serotonin 5-HT2 and 5-HT2B receptors. Potential interactions with these receptors need to be taken into consideration in interpretation of results obtained with Dimebon in HD and AD clinical trials. Further evaluation of Dimebon in AD and HD whole animal models will be required in order to better understand its mechanism of action.
We thank Huarui Liu and Yumei Liu for help with maintaining the YAC128 mouse colony, Leah Benson for administrative assistance, Sarah Bulin and Leah Benson for help with the text editing. This study was supported by R01 NS056224 (IB).
- Vonsattel JP, DiFiglia M: Huntington disease. J Neuropathol Exp Neurol. 1998, 57: 369-84. 10.1097/00005072-199805000-00001.View ArticlePubMedGoogle Scholar
- The Huntington's Disease Collaborative Research and Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72: 971-83. 10.1016/0092-8674(93)90585-E.View ArticleGoogle Scholar
- Tobin AJ, Signer ER: Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 2000, 10: 531-6. 10.1016/S0962-8924(00)01853-5.View ArticlePubMedGoogle Scholar
- Bezprozvanny I, Hayden MR: Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun. 2004, 322: 1310-7. 10.1016/j.bbrc.2004.08.035.View ArticlePubMedGoogle Scholar
- Khachaturian ZS: Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci. 1989, 568: 1-4. 10.1111/j.1749-6632.1989.tb12485.x.View ArticlePubMedGoogle Scholar
- Bezprozvanny I, Mattson MP: Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31 (9): 454-463. 10.1016/j.tins.2008.06.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Bachurin S, et al: Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci. 2001, 939: 425-35.View ArticlePubMedGoogle Scholar
- Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-15. 10.1016/S0140-6736(08)61074-0.View ArticlePubMedGoogle Scholar
- Grigorev VV, Dranyi OA, Bachurin SO: Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med. 2003, 136: 474-7. 10.1023/B:BEBM.0000017097.75818.14.View ArticlePubMedGoogle Scholar
- Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO: Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med. 2001, 132: 1079-83. 10.1023/A:1017972709652.View ArticlePubMedGoogle Scholar
- Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO: Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003, 993: 334-44.View ArticlePubMedGoogle Scholar
- Tang T-S, et al: Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci USA. 2005, 102: 2602-2607. 10.1073/pnas.0409402102.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu J, Tang T-S, Bezprozvanny I: Evaluation of clinically-relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci Lett. 2006, 407: 219-223. 10.1016/j.neulet.2006.08.036.View ArticlePubMedGoogle Scholar
- Tang TS, Chen X, Liu J, Bezprozvanny I: Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci. 2007, 27: 7899-910. 10.1523/JNEUROSCI.1396-07.2007.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I: Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis. 2008, 31: 80-8. 10.1016/j.nbd.2008.03.010.PubMed CentralView ArticlePubMedGoogle Scholar
- Tang T-S, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I: Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 2003, 39: 227-239. 10.1016/S0896-6273(03)00366-0.PubMed CentralView ArticlePubMedGoogle Scholar
- Bargas J, Howe A, Eberwine J, Cao Y, Surmeier DJ: Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons. J Neurosci. 1994, 14: 6667-86.PubMedGoogle Scholar
- Milnerwood AJ, Raymond LA: Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol. 2007, 585: 817-31. 10.1113/jphysiol.2007.142448.PubMed CentralView ArticlePubMedGoogle Scholar
- Hung D: HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE. WO/2007/041697, USA. 2007Google Scholar
- Stavrovskaya IG, et al: Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med. 2004, 200: 211-22. 10.1084/jem.20032053.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.